Gnq Insilico’s Ai-driven Digital Twin Platform Shows Promising Results In First Virtually Simulated Clinical Drug Trial

Trenchant Technologies Capital’s portfolio company GNQ Insilico has demonstrated promising results in synthesizing digital twins of human patients and simulating the effects of an infertility drug using AI-driven technology. Digital twins have the potential to improve the efficiency and efficacy of clinical trials and reduce the failure rate of new drugs.